Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy

Abstract

Long-term cardiovascular complications of cancer therapy are becoming ever more prevalent due to increased numbers of cancer survivors. Cancer therapy-induced cardiotoxicity (CTIC) is an incompletely understood consequence of various chemotherapies, targeted anti-cancer agents and radiation therapy. It is typically detected clinically by a reduction in cardiac left ventricular ejection fraction, assessed by echocardiography. However, once cardiac functional decline is apparent, this indicates irreversible cardiac damage, highlighting a need for the development of diagnostics which can detect CTIC prior to the onset of functional decline. There is increasing evidence to suggest that pathological alterations to cardiac metabolism play a crucial role in the development of CTIC. This review discusses the metabolic alterations and mechanisms which occur in the development of CTIC, with a focus on doxorubicin, trastuzumab, imatinib, ponatinib, sunitinib and radiotherapy. Potential methods to diagnose and predict CTIC prior to functional cardiac decline in the clinic are evaluated, with a view to both biomarker and imaging-based approaches. Finally, the therapeutic potential of therapies which manipulate cardiac metabolism in the context of adjuvant cardioprotection against CTIC is examined. Together, an integrated view of the role of metabolism in pathogenesis, diagnosis and treatment is presented.

Cardiovascular-Specific Mortality among Gastrointestinal Stromal Tumor Patients: A Population-Based Analysis

“…In terms of the year of diagnosis, our study showed that the HRs of CVM for patients diagnosed with GIST in 2000-2004, 2005-2009, 2010-2014, and 2015-2019 decreased consistently across time. The key factor underlying this finding might be that advances in imaging techniques and biomarkers in cardiovascular disease enabled earlier detection and intervention [ 25 ]. In addition, thalidomide and metformin have been shown to have potential cardioprotective effects, preventing the cardiotoxicity of chemotherapeutic agents at the human and animal levels [ 26 , 27 ].…”

Myocardial protection of propofol on apoptosis induced by anthracycline by PI3K/AKT/Bcl-2 pathway in rats

“…Associated with intensive chemotherapy drugs, cardiotoxicity is a common lethal complication in the growing population of cancer survivors (18)(19)(20). The ANTs are among the most cardiotoxic, and are associated with dose-related cardiomyocyte injury and death leading to left ventricular dysfunction and heart failure (21).…”

Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities

“…These toxicities not only have significant short- and long-term impacts on patients’ quality of life but also negatively affect treatment efficacy and patient prognosis. The pathophysiology of these toxicities represents complex processes and involves the interaction between tissue injury, oxidative stress, and inflammation [ 65 , 66 ]. Given the protective, anti-inflammatory, and antioxidant properties of SCFAs [ 67 ], these metabolites have been found to attenuate the severity of these toxicities.…”